Jazz Pharmaceuticals is trading 25.78% down at $178.55 after-hours on September 22, 2026, with the catalyst unclear.
- The price compares with a regular-session close of $240.57.
- No credible company-specific announcement, earnings release, regulatory action or late-breaking news directly explaining the decline was identified.
- Recent coverage discussed earlier oncology growth and financing activity, while broader markets were comparatively stable.